Written Question · S3W-39591 · Session 3
Which NHS boards provide funding for eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria.
The question
To ask the Scottish Executive which NHS boards provide funding for eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria.
The answer
Eculizumab is not recommended by the Scottish Medicines Consortium for use within NHSScotland. As a result, each individual case needs to be considered by the host NHS board according to the specific needs of each individual patient.
Information is available for Scottish patients in the care of the UK designated specialist service at the outreach clinic in Monklands Hospital, Lanarkshire. At present, eculizumab has been approved for the treatment of individual patients with paroxysmal nocturnal haemoglobinuria in five areas
- NHS Lanarkshire, NHS Forth Valley, NHS Ayrshire and Arran, NHS Greater Glasgow and Clyde and NHS Lothian.
Information is available for Scottish patients in the care of the UK designated specialist service at the outreach clinic in Monklands Hospital, Lanarkshire. At present, eculizumab has been approved for the treatment of individual patients with paroxysmal nocturnal haemoglobinuria in five areas
- NHS Lanarkshire, NHS Forth Valley, NHS Ayrshire and Arran, NHS Greater Glasgow and Clyde and NHS Lothian.
In the Official Report
No contribution in the Official Report cites S3W-39591 by reference.